Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions related to the Protecting Patient Access to Cancer and Complex Therapies Act reintroduction Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration Issues regarding 340B program
2026 · 2nd Quarter (Apr 1 - June 30)
DAIICHI SANKYO INC
Filed by DAIICHI SANKYO, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 19, 2026
- Income
- Not reported
- Expenses
- $380,000.00
- Registrant
- DAIICHI SANKYO, INC.
- Client
- DAIICHI SANKYO INC
- Filing UUID
- 7695bc6b-4146-4790-93a1-5b0440fdc4cf
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Discussions regarding tax reform and tariffs
Issues related to the Medicare Drug Price Negotiation Program Issues regarding the GLOBE model
Issues related to intellectual property rights
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.